The US Food and Drug Administration (FDA) has approved the first intranasal diuretic for heart, liver and kidney disease ...

The U.S. regulator has signed off on Corstasis Therapeutics’ Enbumyst to relieve the edema associated with congestive heart ...

The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of bumetanide, for the treatment of edema associated with congestive heart failure (CHF), and hepatic and ...

Corstasis Therapeutics Inc., an innovative biopharmaceutical company providing enhanced outpatient therapeutic options for ...

Nevada-based Corstasis Therapeutics (Corstasis) has announced FDA’s approval of its bumetanide nasal spray, Enbumyst, for the ...

The FDA has approved a new flu vaccine nasal spray for at-home use. While this self-administered version won't be available for this year's flu season, interest in nasal spray products is growing. A ...

FILE - Food and Drug Administration (FDA) building is shown in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) (Manuel Balce Ceneta, Copyright ...

The U.S. Food and Drug Administration (FDA) has approved FluMist — the nasal spray flu vaccine — for home use by a patient or adult caregiver, the agency announced. FluMist has been in use for a ...

New breakthrough research suggests that a common, over-the-counter nasal spray used to treat allergies may protect against ...

The FDA has approved Enbumyst (bumetanide nasal spray) for treating edema linked to congestive heart failure, liver disease, ...